C4 Therapeutics Inc (CCCC)

$4.24 +0.16 (3.92%)
Market Cap 521.63M
Revenue (ttm) 35.95M
Net Income (ttm) -104.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -292.04%
Debt to Equity Ratio 0.00
Volume 3,399,000
Avg Vol 3,169,906
Day's Range N/A - N/A
Shares Out 123.03M
Stochastic %K 91%
Beta 2.91
Analysts Strong Sell
Price Target $13.33

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
LabPsycho
LabPsycho Aug. 14 at 3:53 PM
$CCCC @zawojak I think you hit the nail on the head..."working out for THEM long term" - not existing shareholders. Why buy or own this or any biotech with these ATM / warrants when you know management will mute significant gains with the dumping of shares / warrants for who knows how long (probably as long as the company is existence. ?
2 · Reply
JuggernautRaider
JuggernautRaider Aug. 14 at 2:57 PM
$KPTI $PFE $CCCC $BMY ⚾️ 🥧 🇺🇸 💪 🏦 🤷‍♂️ 💊 🏃‍♂️ Keep slugging America. We got this. 🏆
0 · Reply
zawojak
zawojak Aug. 14 at 10:01 AM
$CCCC Vanguard increased its cccc position by almost 15%.
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 9:16 PM
$BMY Iber approved, buy some $CCCC
1 · Reply
LabPsycho
LabPsycho Aug. 13 at 4:41 PM
$CCCC 1 quarter early but patting myself on the back for this predition...they do have more $$$ than before...active ATM. Explains why this trades so many shares but moves are muted. Every run greeted with a $$$ dump. But hey, if the (gradual) trend is up..so what.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 4:32 PM
$CCCC Soon we'll reach the demonic battlegrounds at $6.66 where the class B warrants hide
0 · Reply
Jh900
Jh900 Aug. 13 at 4:03 PM
$CCCC
0 · Reply
zawojak
zawojak Aug. 13 at 4:03 PM
$CCCC to da mooooooonaaaaa !!! Buy below $5 !!!! Train is choooo choooing !!! F ya!
1 · Reply
venice868
venice868 Aug. 13 at 3:51 PM
$CCCC time to ride
0 · Reply
open_outcry
open_outcry Aug. 13 at 3:44 PM
$CCCC they gonna let it run today?
0 · Reply
Latest News on CCCC
C4 Therapeutics reports Q2 EPS (18c), consensus (23c)

2026-08-11T11:10:28.000Z - 5 days ago

C4 Therapeutics reports Q2 EPS (18c), consensus (23c)

C4 Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 5 days ago

C4 Therapeutics Earnings release: Q2 2026

C4 Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 5 days ago

C4 Therapeutics Quarterly report: Q2 2026

C4 Therapeutics Slides: Corporate presentation

Aug 10, 2026, 7:00 AM EDT - 6 days ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics Transcript: AGM 2026

Jun 24, 2026, 8:30 AM EDT - 7 weeks ago

C4 Therapeutics Transcript: AGM 2026

C4 Therapeutics Transcript: KOL event

Jun 18, 2026, 9:00 AM EDT - 2 months ago

C4 Therapeutics Transcript: KOL event

C4 Therapeutics Slides: KOL event

Jun 18, 2026, 9:00 AM EDT - 2 months ago

C4 Therapeutics Slides: KOL event

C4 Therapeutics presents further analysis from cemsidomide trial

2026-06-11T12:00:29.000Z - 2 months ago

C4 Therapeutics presents further analysis from cemsidomide trial

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Jun 11, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics Slides: Corporate presentation

Jun 11, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:20 AM EDT - 2 months ago

C4 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

C4 Therapeutics jumps after Bristol Myers myeloma data

2026-05-29T15:51:38.000Z - 2 months ago

C4 Therapeutics jumps after Bristol Myers myeloma data

BMY

C4 Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 2:30 PM EDT - 2 months ago

C4 Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026, 4:01 PM EDT - 3 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

2026-05-12T12:40:38.000Z - 3 months ago

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Quarterly report: Q1 2026

C4 Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Earnings release: Q1 2026

C4 Therapeutics Slides: Investor presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Slides: Investor presentation

C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

C4 Therapeutics Proxy statement: Proxy filing

C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

C4 Therapeutics Proxy statement: Proxy filing

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

Apr 9, 2026, 9:34 AM EDT - 4 months ago

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics expands long-term partnership with Roche

2026-04-09T11:07:07.000Z - 4 months ago

C4 Therapeutics expands long-term partnership with Roche

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Apr 9, 2026, 6:59 AM EDT - 4 months ago

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 4 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics doses first patient in cemsidomide trial

2026-03-25T11:25:28.000Z - 5 months ago

C4 Therapeutics doses first patient in cemsidomide trial

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 25, 2026, 7:00 AM EDT - 5 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 5 months ago

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 5 months ago

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

C4 Therapeutics Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 5 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics price target raised to $7 from $5 at Barclays

2026-02-27T10:25:32.000Z - 6 months ago

C4 Therapeutics price target raised to $7 from $5 at Barclays

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

2026-02-26T12:08:51.000Z - 6 months ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Annual report: Q4 2025

C4 Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Earnings release: Q4 2025

C4 Therapeutics Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics price target raised to $30 from $20 at Brookline

2026-02-23T17:07:13.000Z - 6 months ago

C4 Therapeutics price target raised to $30 from $20 at Brookline

C4 Therapeutics to Participate in Upcoming March Conferences

Feb 23, 2026, 7:10 AM EST - 6 months ago

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

2026-02-23T12:06:05.000Z - 6 months ago

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 23, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 11:30 AM EST - 6 months ago

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics outlines milestones through 2028

2026-01-14T12:05:59.000Z - 7 months ago

C4 Therapeutics outlines milestones through 2028

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Jan 14, 2026, 7:00 AM EST - 7 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics price target lowered to $5 from $10 at Barclays

2025-12-17T10:55:09.000Z - 8 months ago

C4 Therapeutics price target lowered to $5 from $10 at Barclays

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 9 months ago

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

C4 Therapeutics initiated with a Buy at TD Cowen

2025-12-02T10:40:12.000Z - 9 months ago

C4 Therapeutics initiated with a Buy at TD Cowen

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

C4 Therapeutics files $400M mixed securities shelf

2025-11-21T21:10:22.000Z - 9 months ago

C4 Therapeutics files $400M mixed securities shelf

C4 Therapeutics Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 8:30 AM EST - 9 months ago

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

2025-11-06T12:24:51.000Z - 10 months ago

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

C4 Therapeutics sees cash runway to the end of 2028

2025-11-06T12:24:45.000Z - 10 months ago

C4 Therapeutics sees cash runway to the end of 2028

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Earnings release: Q3 2025

C4 Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Quarterly report: Q3 2025

C4 Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 6:00 PM EST - 10 months ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics prices $125M underwritten offering

2025-10-16T11:20:33.000Z - 10 months ago

C4 Therapeutics prices $125M underwritten offering

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Oct 16, 2025, 7:08 AM EDT - 10 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics announces trial collab, supply agreement with Pfizer

2025-10-01T11:10:58.000Z - 11 months ago

C4 Therapeutics announces trial collab, supply agreement with Pfizer

PFE

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Oct 1, 2025, 7:00 AM EDT - 11 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

2025-09-23T10:15:16.000Z - 11 months ago

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

C4 Therapeutics price target raised to $10 from $8 at Barclays

2025-09-22T11:15:14.000Z - 11 months ago

C4 Therapeutics price target raised to $10 from $8 at Barclays

C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Slides: Status Update

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Slides: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 20, 2025, 11:00 AM EDT - 11 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 4, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Sep 3, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q2 2025

C4 Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q2 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q1 2025

C4 Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q1 2025

C4 Therapeutics Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Earnings release: Q4 2024

C4 Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Annual report: Q4 2024

C4 Therapeutics Slides: Corporate Presentation

Feb 26, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

C4 Therapeutics Slides: FY 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Slides: FY 2025

C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Slides: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Slides: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Quarterly report: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q3 2024

C4 Therapeutics Earnings release: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q3 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 8:35 AM EDT - 2 years ago

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Press release: Study Update

C4 Therapeutics Slides: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Slides: Study Update

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 2 years ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 2 years ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 8:45 AM EDT - 2 years ago

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Quarterly report: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q2 2024

C4 Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q2 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 2 years ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jul 15, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q1 2024

C4 Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q1 2024

C4 Therapeutics Slides: Corporate Presentation

May 7, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 16, 2024, 10:30 AM EDT - 2 years ago

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Earnings release: Q4 2023

C4 Therapeutics Annual report: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Annual report: Q4 2023

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

C4 Therapeutics Slides: FY 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Slides: FY 2024

C4 Therapeutics Slides: Corporate Presentation

Jan 11, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Transcript: Study Update

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 3 years ago

C4 Therapeutics Quarterly report: Q3 2023

C4 Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 3 years ago

C4 Therapeutics Earnings release: Q3 2023

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 3 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 3 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

LabPsycho
LabPsycho Aug. 14 at 3:53 PM
$CCCC @zawojak I think you hit the nail on the head..."working out for THEM long term" - not existing shareholders. Why buy or own this or any biotech with these ATM / warrants when you know management will mute significant gains with the dumping of shares / warrants for who knows how long (probably as long as the company is existence. ?
2 · Reply
JuggernautRaider
JuggernautRaider Aug. 14 at 2:57 PM
$KPTI $PFE $CCCC $BMY ⚾️ 🥧 🇺🇸 💪 🏦 🤷‍♂️ 💊 🏃‍♂️ Keep slugging America. We got this. 🏆
0 · Reply
zawojak
zawojak Aug. 14 at 10:01 AM
$CCCC Vanguard increased its cccc position by almost 15%.
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 9:16 PM
$BMY Iber approved, buy some $CCCC
1 · Reply
LabPsycho
LabPsycho Aug. 13 at 4:41 PM
$CCCC 1 quarter early but patting myself on the back for this predition...they do have more $$$ than before...active ATM. Explains why this trades so many shares but moves are muted. Every run greeted with a $$$ dump. But hey, if the (gradual) trend is up..so what.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 13 at 4:32 PM
$CCCC Soon we'll reach the demonic battlegrounds at $6.66 where the class B warrants hide
0 · Reply
Jh900
Jh900 Aug. 13 at 4:03 PM
$CCCC
0 · Reply
zawojak
zawojak Aug. 13 at 4:03 PM
$CCCC to da mooooooonaaaaa !!! Buy below $5 !!!! Train is choooo choooing !!! F ya!
1 · Reply
venice868
venice868 Aug. 13 at 3:51 PM
$CCCC time to ride
0 · Reply
open_outcry
open_outcry Aug. 13 at 3:44 PM
$CCCC they gonna let it run today?
0 · Reply
AliThePoorMan
AliThePoorMan Aug. 13 at 11:46 AM
$TNXP $ALT $CCCC $PFE
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 13 at 11:38 AM
$TNXP why do i only own 0.1% of Tonix Dave Cooper? AKA my favorite neighbor Mister Cooper? Why? 🏦 This should be 10c higher, Rodney! Prop Joe! Hoppanin!! I got FIBROMYALGIA TOO! How come I ain’t got Tonmya yet? WHAT ABOUT MY MAMA??? 😡 $ALT $CCCC $PFE all day every day 💚 💙 💟 ♥️ 🖤 Vamanos, mis amigos! DONDE ESTA MY cerveza? 🍺 jajajajajajaja 😂 197 x 5 =985, or $98.5? I’ll take that, Too 👍 ☘️ 🚀 ☮️ 🇺🇸
0 · Reply
Jh900
Jh900 Aug. 11 at 4:57 PM
$CCCC and we’re off 🔮
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 11 at 3:56 PM
$CCCC 👀
0 · Reply
open_outcry
open_outcry Aug. 11 at 2:00 PM
$CCCC don't see this going down post-earnings, so the question is really stable or up?
0 · Reply
Jh900
Jh900 Aug. 11 at 11:42 AM
$CCCC lovely
0 · Reply
zawojak
zawojak Aug. 11 at 11:17 AM
$CCCC better ER than expected 👌
0 · Reply
zawojak
zawojak Aug. 10 at 9:58 PM
$CCCC they pull it down before ER, classic move MM.
2 · Reply
zawojak
zawojak Aug. 9 at 8:14 PM
$CCCC 5 green days. Lets see how will it next week.
1 · Reply
zawojak
zawojak Aug. 7 at 5:41 PM
$CCCC is getting attention of big players
1 · Reply
lelongduzboob
lelongduzboob Aug. 7 at 4:21 PM
$CCCC well state street corp increase their position by 450%. Fun to see
0 · Reply
Redbet69
Redbet69 Aug. 7 at 2:04 PM
$CCCC What's your opinion about next week and pls what is the next catalyst (I know ER will be next week)
1 · Reply